Global Registry SYMPLICITY demonstrated the safety of renal denervation system

The Global SYMPLICITY registry is a prospective, multicenter study sponsored by Medtronic to evaluate long- term renal denervation safety and effectiveness in a real-world population with refractory hypertension. It plans to prospectively include a minimum of 5000 patients with refractory hypertension in 200 centers worldwide.In the 6-month analysis of the first 1000 patients included so far, showed adverse event rate of less than 1% and the absence of renal artery stenosis related to the procedure.The reduction in systolic blood pressure over the outpatientoffice was 11.9 mmHgand reduced pressure of 24 hour ambulatory monitoring was 7.9 mmHg.

Despite the record of GlobalSYMPLICITY registry is currently the largest on denervation of the renal artery and demonstrated safety and efficacy of the device overall discussions revolve around the negative results of randomized SIMPLICITY HTN 3.

5_michael_bohm
Michael Bohm
2014-03-31

Original title: The Global SYMPLICITY Registry: Safety and Effectiveness of Renal Artery Denervation In Real World Patients With Uncontrolled Hypertension.

 

More articles by this author

CORP-2 Trial: Colchicine effective in reducing the recurrence of pericarditis associated withconventional anti-inflammatory pattern.

Colchicine is effective in treating an acute pericarditis event and initial recurrences;however, there is no conclusive data on its efficacy and safety in the...

Melody

The ducts of the right ventricle to the pulmonary artery are used in approximately 20 % of all patients with congenital defects including tetralogy...

Negative ultrasensitive troponin T values may help discriminate patients with chest pain in the emergency

New laboratory tests can detect minimally elevated  levels few hours before regarding detection methodologies of previous generations.The hypothesis of this study is that patients...

LAPLACE 2: Evolocumab effective in reducing LDL associated with statins

There are several patients who do not reach recommended LDL cholesterol despite maximally tolerated doses of statins levels.The Evolocumab is a monoclonal antibody that...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Long Term Results of the International Chimney Registry

The International Chimney Registry was an observational study aimed at assessing the use of chimney stenting during TAVR either to predict or treat coronary...

CANNULATE TAVR extended study: Impact of Commissural and Coronary Alignment in Coronary Cannulation Following TAVR with Evolut Fx

The new valve Evolut FX has shown better commissural alignment vs. its predecessor Evolut Pro+. Prior studies have already shown commissure alignment facilitates post...

TRISCEND II: Transcatheter Replacement vs. Medical Treatment for Tricuspid Regurgitation

The EVOQUE device is designed with an intra-annular sealing system that provides excellent anatomical compatibility and an adaptable shape. It is currently available in...